Enlicitide, an oral PCSK9 inhibitor, reduced LDL-C by nearly 60% in adults with or at risk for ASCVD. The medication offers a daily oral alternative to injectable PCSK9 inhibitors, potentially ...
Please provide your email address to receive an email when new articles are posted on . An oral PCSK9 inhibitor lowered LDL cholesterol by up to 60% and improved other lipid parameters at 24 weeks.
In a recent study published in the Scientific Reports Journal, researchers from Japan conducted a longitudinal study investigating the association between white blood cell count and hypercholesteremia ...
Hosted on MSN
New pill shows 60 per cent LDL reduction in trials: Cardiologists break down if it reduces heart attack risk
High levels of low-density lipoprotein cholesterol (LDL-C) are a key risk factor for cardiovascular disease, which continues to be one of the leading causes of illness and death globally. LDL-C can ...
Patients with severe hypercholesterolemia who are unresponsive to a number of lipid-lowering therapies, including a PCSK9 inhibitor and high-dose statin, can have a significant reduction in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback